QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
NYSE:PRGO

Perrigo - PRGO Stock Forecast, Price & News

$36.29
-0.91 (-2.45%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$36.14
▼
$37.22
50-Day Range
$31.12
▼
$37.72
52-Week Range
$30.78
▼
$43.90
Volume
916,249 shs
Average Volume
860,088 shs
Market Capitalization
$4.89 billion
P/E Ratio
N/A
Dividend Yield
2.80%
Price Target
$47.33

Perrigo MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
30.4% Upside
$47.33 Price Target
Short Interest
Healthy
4.21% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.93
Upright™ Environmental Score
News Sentiment
0.47mentions of Perrigo in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$74,947 Sold Last Quarter
Proj. Earnings Growth
37.62%
From $2.02 to $2.78 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.92 out of 5 stars

Medical Sector

23rd out of 1,027 stocks

Pharmaceutical Preparations Industry

9th out of 500 stocks

See Top Rated MarketRank™ Stocks Here
PRGO stock logo

About Perrigo (NYSE:PRGO) Stock

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Stock News Headlines

December 26, 2022 | thestreet.com
Perrigo (PRGO) Stock Plunging on Failed Mylan Deal
December 19, 2022 | finance.yahoo.com
Perrigo to Host Virtual Investor Day on February 28, 2023
February 7, 2023 | Investing Trends (Ad)
GRAPHITE: "Essential for America's National Defense"
Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.
December 16, 2022 | finance.yahoo.com
SWEDEN’S SKINCARE SENSATION ACO EXTENDS PRESENCE INTO US TIMED TO THE HOLIDAY SEASON
December 16, 2022 | investing.com
Perrigo Co. PT Lowered to $45 at JPMorgan
December 1, 2022 | finance.yahoo.com
Reckitt Benckiser expects baby formula shortage to continue into spring 2023
November 10, 2022 | finance.yahoo.com
‘Long-term investors should turn back toward stocks’: J.P. Morgan says inflation has peaked and suggests 2 stocks to buy
November 8, 2022 | finance.yahoo.com
Why Perrigo Stock Tanked on Tuesday
February 7, 2023 | Wall Street Watch Dogs (Ad)
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
November 8, 2022 | finance.yahoo.com
Perrigo Shares Fall As Investors React To Lowered FY22 Profit Guidance
November 8, 2022 | finance.yahoo.com
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View
November 8, 2022 | benzinga.com
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
November 8, 2022 | finance.yahoo.com
Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations
November 8, 2022 | finance.yahoo.com
Perrigo stock slides premarket after earnings miss as strong dollar and labor shortages weigh
November 7, 2022 | finance.yahoo.com
Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?
November 2, 2022 | finance.yahoo.com
Analysts Estimate PetIQ (PETQ) to Report a Decline in Earnings: What to Look Out for
November 1, 2022 | finance.yahoo.com
Perrigo (PRGO) Earnings Expected to Grow: Should You Buy?
October 26, 2022 | markets.businessinsider.com
Perrigo: FDA Postpones Meeting To Review Additional Information Requested Related To Opill
October 26, 2022 | seekingalpha.com
Perrigo drops as FDA postpones AdCom meeting on OTC birth control pill
October 26, 2022 | reuters.com
U.S. FDA delays panel meet on Perrigo's OTC contraceptive pill
October 26, 2022 | finance.yahoo.com
Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter (OTC) Use
October 25, 2022 | finance.yahoo.com
Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022
October 24, 2022 | finance.yahoo.com
Perrigo Company plc (PRGO)
October 20, 2022 | seekingalpha.com
Perrigo: Back On Track (NYSE:PRGO) - Seeking Alpha
October 15, 2022 | finance.yahoo.com
SSDI Beneficiaries to Receive 8.7% Increase in Monthly Benefits, Highest in 40 Years, Allsup Reports - Yahoo Finance
October 13, 2022 | nasdaq.com
Perrigo Company (PRGO) Shares Cross Above 200 DMA - Nasdaq
October 13, 2022 | streetinsider.com
SSDI Beneficiaries to Receive 8.7% Increase in Monthly Benefits, Highest in 40 Years, Allsup Reports - StreetInsider.com
See More Headlines
Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Company Calendar

Last Earnings
11/10/2021
Ex-Dividend for 12/20 Dividend
12/01/2022
Dividend Payable
12/20/2022
Today
2/07/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:PRGO
CUSIP
71429010
CIK
1585364
Web
www.perrigo.com
Phone
(531) 709-4000
Fax
269-673-9128
Employees
9,900
Year Founded
1887

Price Target and Rating

Average Stock Price Forecast
$47.33
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+30.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
17.97
P/E Growth
N/A
Net Income
$-68,900,000.00
Net Margins
-1.93%
Pretax Margin
-2.61%
Return on Equity
5.31%
Return on Assets
2.47%

Debt

Debt-to-Equity Ratio
0.89
Current Ratio
2.55
Quick Ratio
1.48

Sales & Book Value

Annual Sales
$4.14 billion
Price / Sales
1.18
Cash Flow
$4.27 per share
Price / Cash Flow
8.49
Book Value
$38.51 per share
Price / Book
0.94

Miscellaneous

Outstanding Shares
134,640,000
Free Float
133,563,000
Market Cap
$4.89 billion
Optionable
Optionable
Beta
0.81

Social Links


Key Executives

  • Murray S. Kessler
    President, Chief Executive Officer & Director
  • Ronald C. JanishRonald C. Janish
    Executive VP-Global Operations and Supply Chain
  • Eduardo Guarita Bezerra
    Chief Financial Officer & Executive Vice President
  • Thomas M. FarringtonThomas M. Farrington
    Chief Information Officer & Executive VP
  • Grainne Quinn
    Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRGO Stock - Frequently Asked Questions

Should I buy or sell Perrigo stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRGO shares.
View PRGO analyst ratings or view top-rated stocks.

What is Perrigo's stock price forecast for 2023?

3 brokers have issued twelve-month price objectives for Perrigo's shares. Their PRGO share price forecasts range from $42.00 to $54.00. On average, they expect the company's stock price to reach $47.33 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price.
View analysts price targets for PRGO or view top-rated stocks among Wall Street analysts.

How have PRGO shares performed in 2023?

Perrigo's stock was trading at $34.09 at the start of the year. Since then, PRGO stock has increased by 6.5% and is now trading at $36.29.
View the best growth stocks for 2023 here.

Are investors shorting Perrigo?

Perrigo saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 5,670,000 shares, an increase of 17.1% from the December 31st total of 4,840,000 shares. Based on an average trading volume of 1,480,000 shares, the short-interest ratio is presently 3.8 days.
View Perrigo's Short Interest.

When is Perrigo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our PRGO earnings forecast.

How were Perrigo's earnings last quarter?

Perrigo Company plc (NYSE:PRGO) posted its earnings results on Wednesday, November, 10th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.65 by $0.20. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.05 billion. Perrigo had a positive trailing twelve-month return on equity of 5.31% and a negative net margin of 1.93%. During the same period in the previous year, the business earned $0.93 EPS.
Read the conference call transcript.

How often does Perrigo pay dividends? What is the dividend yield for Perrigo?

Perrigo announced a quarterly dividend on Thursday, November 3rd. Shareholders of record on Friday, December 2nd will be given a dividend of $0.26 per share on Tuesday, December 20th. This represents a $1.04 annualized dividend and a yield of 2.87%. The ex-dividend date is Thursday, December 1st.
Read our dividend analysis for PRGO.

Is Perrigo a good dividend stock?

Perrigo (NYSE:PRGO) pays an annual dividend of $1.04 per share and currently has a dividend yield of 2.80%.
Read our dividend analysis for PRGO.

What guidance has Perrigo issued on next quarter's earnings?

Perrigo updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of $2.00-$2.10 for the period, compared to the consensus earnings per share estimate of $2.28. The company issued revenue guidance of $4.49 billion-$4.53 billion, compared to the consensus revenue estimate of $4.53 billion.

What is Murray S. Kessler's approval rating as Perrigo's CEO?

38 employees have rated Perrigo Chief Executive Officer Murray S. Kessler on Glassdoor.com. Murray S. Kessler has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Perrigo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), AbbVie (ABBV), Allergan (AGN), Intel (INTC), Johnson & Johnson (JNJ), Netflix (NFLX), QUALCOMM (QCOM) and Amgen (AMGN).

What is Perrigo's stock symbol?

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Who are Perrigo's major shareholders?

Perrigo's stock is owned by many different retail and institutional investors. Top institutional shareholders include Coho Partners Ltd. (2.67%), DAVENPORT & Co LLC (2.23%), Pendal Group Ltd (1.82%), Ceredex Value Advisors LLC (0.84%), Copeland Capital Management LLC (0.83%) and ProShare Advisors LLC (0.60%). Insiders that own company stock include Bradley A Alford, Geoffrey M Parker, Grainne Quinn, Raymond Silcock, Richard S Sorota, Rolf A Classon, Ronald Craig Janish, Svend Andersen, Theodore R Samuels II, Thomas Farrington and Todd W Kingma.
View institutional ownership trends.

How do I buy shares of Perrigo?

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Perrigo's stock price today?

One share of PRGO stock can currently be purchased for approximately $36.29.

How much money does Perrigo make?

Perrigo (NYSE:PRGO) has a market capitalization of $4.89 billion and generates $4.14 billion in revenue each year. The company earns $-68,900,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How many employees does Perrigo have?

The company employs 9,900 workers across the globe.

Does Perrigo have any subsidiaries?
The following companies are subsidiares of Perrigo: 010414 UK Limited, 251211 UK Limited, Abtei Omega Pharma GmbH, Aco Hud Nordic AB, Adriatic BST Trgovina in Storitve D.o.o., Adriatic Distribution doo Beograd, Agis Industries, Algorithmics Risk Management Limited, Arginet Investments and Property (2003) Ltd., Athena Neurosciences LLC, Aurora Pharmaceuticals Pty Ltd, Biover NV, Blue Wolf Global Limited, Bluewolf International Limited, Brunel Healthcare Manufacturing Limited, CP Kayak Holdings Inc., CanNegev Ltd, Chefaro Ireland Designated Activity Company, Cinetic Laboratories Argentina SA, Cleversafe UK Limited, Cosmediet - Biotechnie SAS, Despharma Kft., Elan Corporation, Elan Europa Finance S.á r.l., Elan International Services Limited, Elan Pharmaceuticals LLC, Fera Pharmaceuticals, Galpharm Healthcare Limited, Galpharm International, Galpharm International Limited, Geiss Destin & Dunn, Gelcaps Exportadora de Mexico S.A. de C.V., Gr8ness LLC, HRA Pharma, Habsont Unlimited Company, Heartbeat Experts Limited, IBM GF international Treasury Company, IBM International Treasury Services Unlimited Company, IBM Netherlands Treasury B.V., Interdelta S.A., International Business Machines Limited, Irish Biosciences Venture Capital Fund, JB Laboratories, JLR Pharma S.A., Jaico R.D.P. NV, Jewel Consumer Care Pvt. Ltd., Kazmira LLC, Kenexa Global Recruitment Services Limited, Kenexa Quorum Holdings Limited, Kenexa Technology LLC, Kiteacre Limited, L. Perrigo Company, Laboratoire de la Mer SAS, Laboratoires Omega Pharma France SAS, Laboratorios DIBA S.A., Laboratorios Diba, Luxembourg Investment Company 289 Sàrl, MH (UK) Limited, Medgenix Benelux NV, Monksland Holdings B.V., Naturwohl Pharma GmbH, ORION Laboratories, Oce Bio BV, Oce-Bio Nederland B.V., Omega Alpharm Cyprus Ltd., Omega Pharma, Omega Pharma AS, Omega Pharma Australia Pty Ltd, Omega Pharma Austria Healthcare GmbH, Omega Pharma Baltics SIA, Omega Pharma Belgium NV, Omega Pharma Capital NV, Omega Pharma Deutschland GmbH, Omega Pharma GmbH, Omega Pharma Hellas SA Health and Beauty Products, Omega Pharma Hungary Kft., Omega Pharma Innovation & Development NV, Omega Pharma International NV, Omega Pharma Limited, Omega Pharma Luxembourg SarL, Omega Pharma Manufacturing GmbH & Co. KG, Omega Pharma Manufacturing Verwaltungs GmbH, Omega Pharma Nederland B.V., Omega Pharma Trading NV, Omega Pharma s.r.o., Omega Teknika Designated Activity Company, OmegaLabs (Pty) Ltd, Oniqua Europe Limited, Optevia Limited, Orion Laboratories (NZ) Ltd., Orion Laboratories PTY Limited, P-Direct NL B.V., P2C Inc., PBM Canada Holdings LLC, PBM China Holdings LLC, PBM Foods LLC, PBM Holdings LLC, PBM International Holdings LLC, PBM Mexico Holdings LLC, PBM Nutritionals LLC, PBM Products, PBM Products LLC, PBM Products Mexico S de R.L. de C.V., PMI Branded Pharmaceuticals Inc., Paddock Laboratories, Paracelsia Pharma GmbH, Perrigo Asia Holding Company Ltd., Perrigo Australian Holding Company II PTY Limited, Perrigo Bulgaria OOD, Perrigo China Business Trust, Perrigo China Business Trustee LLC, Perrigo Company, Perrigo Company Charitable Foundation, Perrigo Company of Tennessee, Perrigo Company plc, Perrigo Corporation Designated Activity Company, Perrigo Danmark A/S, Perrigo Diabetes Care LLC, Perrigo Direct Inc., Perrigo España SA, Perrigo Europe Invest NV, Perrigo Finance (US) LLC, Perrigo Finance Unlimited Company, Perrigo Florida Inc., Perrigo France SAS, Perrigo Global Holdings Inc., Perrigo Holding NV, Perrigo Holdings Unlimited Company, Perrigo International Finance Designated Activity Company, Perrigo International Holdings II Inc., Perrigo International Holdings LLC, Perrigo International Inc., Perrigo International Insurance Limited, Perrigo Ireland 1 Designated Activity Company, Perrigo Ireland 10 Unlimited Company, Perrigo Ireland 11 DAC, Perrigo Ireland 12 Designated Activity Company, Perrigo Ireland 13 Designated Activity Company, Perrigo Ireland 2 Designated Activity Company, Perrigo Ireland 3 Designated Activity Company, Perrigo Ireland 4 Unlimited Company, Perrigo Ireland 5 Unlimited Company, Perrigo Ireland 6 Unlimited Company, Perrigo Ireland 7 Designated Activity Company, Perrigo Ireland 8 Designated Activity Company, Perrigo Ireland 9 Unlimited Company, Perrigo Ireland Holding Company B.V., Perrigo Ireland Management Designated Activity Company, Perrigo Israel Enterprises & Investments Ltd., Perrigo Israel Holdings II B.V., Perrigo Israel Opportunities II Ltd., Perrigo Israel Trading Limited Partnership, Perrigo Italia S.r.l, Perrigo Kişisel Bakım Ürünleri Sanayi ve Ticaret Limited Şirketi, Perrigo LLC, Perrigo Laboratories India Private Limited, Perrigo Management Company, Perrigo Mexico Holding S.A. de C.V., Perrigo Mexico Investment Holdings LLC, Perrigo Netherlands B.V., Perrigo Netherlands Finco 1 Coöperatief U.A., Perrigo Netherlands Finco 2 B.V., Perrigo Netherlands International Partnership C.V., Perrigo New York Inc., Perrigo Norge AS, Perrigo Oral Health Care Holdings Inc., Perrigo Pharma Holding Nederland BV, Perrigo Pharma International Designated Activity Company, Perrigo Pharma Limited, Perrigo Poland Sp.z.o.o, Perrigo Portugal LDA, Perrigo Research & Development Company, Perrigo România S.R.L., Perrigo Sales Corporation, Perrigo Science Eight Unlimited Company, Perrigo Science One Designated Activity Company, Perrigo Suomi Oy, Perrigo Sverige AB, Perrigo Trading (Shanghai) Co. Ltd., Perrigo UK Acquisition Limited, Perrigo UK Finco Limited Partnership, Perrigo Ukraine LLC, Perrigo Ventures Limited Partnership, Perrigo de Mexico S.A. de C.V., Perrigo do Brasil Farmaceutica Ltda., Pharma Clal (1983) Ltd., Promontory Financial Group (UK) Limited, Quimica y Farmacia S.A. de C.V., Ranir, Ranir (Holdings) Limited, Ranir Changshu Oral Care CO. Ltd., Ranir Global Holdings LLC, Ranir LLC, Ranir Limited, Resilient Systems Europe Limited, Richard Bittner AG, Rosemont Pharmaceuticals, Rubicon Healthcare Holdings Pty Ltd, SPSS Limited, Samenwerkende Apothekers Nederland B.V., ScarAway, Silverpop Systems Limited, Simpler Consulting Limited, Solent Dental Company Limited, Solent Oral Care Limited, Sterling Commerce (UK) Limited, The Analytic Sciences Corporation Limited, The Learning Pharmacy Limited, The Weather Channel Global Media Limited, Totalcare International Corp, Transitive Corporation Limited, Transitive Limited, Truven Health Analytics UK Limited, Velcera, Weather Services International Limited, Wrafton Laboratories, Wrafton Laboratories Limited, Zibo Xinhua - Perrigo Pharmaceutical Company Ltd., i2 Holdings Limited, i2 Intermediate Holdings Limited, and i2 Limited.
Read More
How can I contact Perrigo?

Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The official website for the company is www.perrigo.com. The company can be reached via phone at (531) 709-4000, via email at bradley.joseph@perrigo.com, or via fax at 269-673-9128.

This page (NYSE:PRGO) was last updated on 2/7/2023 by MarketBeat.com Staff